Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Lenalidomide for CAEBV
NCT04518982Phase 2Unknown
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, lenalidomide in chronic active Epstein-Barr virus infection (CAEBV). Status: unknown.
02
Drugs
sintilimablenalidomide
03
Conditions
chronic active Epstein-Barr virus infection (CAEBV)
Beyond the preview
Go deeper on NCT04518982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518982.